Novo Nordisk will take Dicerna's technology to the next level, says EVP
Dicerna's technology platform will presumably result in several new drug candidates within Novo Nordisk's disease areas, says Executive Vice President & Chief Scientific Officer at Novo Nordisk Marcus Schindler.
by marketwire, translated by daniel pedersen
Novo Nordisk's acquisition of the US-based biotech company for USD 3.3bn follows a two-year-long successful collaboration, and signals that more drug candidates from Dicerna's technology platform targeting Novo's focus areas could be on their way in the future, says Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk, to MarketWire.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Huge acquisition scores Novo Nordisk an FDA-ready treatment
For subscribers
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
